Article
Oncology
Justyna Wos, Sylwia Chocholska, Wioleta Kowalska, Waldemar Tomczak, Agata Szymanska, Agnieszka Karczmarczyk, Agnieszka Szuster-Ciesielska, Agnieszka Wojciechowska, Agnieszka Bojarska-Junak
Summary: TEMs, characterized by the phenotype of CD14+CD16+Tie2+, have been identified as a new immunosuppressive force in tumors and are associated with unfavorable prognosis in CLL patients. Despite not being an independent predictor of survival, TEM can serve as an important complement to other prognostic indicators in CLL patients.
Article
Oncology
Rui Xue, Yuqiao Sheng, Xixi Duan, Yang Yang, Shengli Ma, Jingjing Xu, Na Wei, Xiaoping Shang, Feng Li, Jiajia Wan, Zhihai Qin
Summary: The study found that the frequency of TEMs in the peripheral blood of lung cancer patients was significantly higher than in patients with benign pulmonary disease and healthy controls, and was positively correlated with NSCLC recurrence and microvascular density. A high TEM frequency was associated with poor overall survival. Circulating TEM frequency may serve as a diagnostic marker for NSCLC.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Cardiac & Cardiovascular Systems
M. Reijrink, J. van Ark, C. P. H. Lexis, L. M. Visser, M. E. Lodewijk, I. C. C. van der Horst, C. J. Zeebregts, H. van Goor, S. C. A. de Jager, G. Pasterkamp, B. H. R. Wolffenbuttel, J. L. Hillebrands
Summary: The study found that the distribution of monocyte subsets is altered in individuals with type 2 diabetes, with reduced non-classical monocytes and increased percentage of pro-angiogenic monocytes expressing Tie2 in the intermediate subset. Additionally, higher levels of angiopoietin-2 in the plasma of T2DM patients may increase plaque vulnerability.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Oncology
Ha -Ram Park, Anahita Shiva, Portia Cummings, Seoyeon Kim, Sungsoo Kim, Eunhyeong Lee, Alessandra Leong, Subrata Chowdhury, Carrie Shawber, Richard Carvajal, Gavin Thurston, Joon-Yong An, Amanda W. Lund, Hee Won Yang, Minah Kim
Summary: The position of T-cells in the tumor microenvironment affects their ability to encounter the tumor and kill it. The vascular destabilizing factor ANGPT2 causes vascular integrity issues in the tumor periphery, leading to a lack of T-cell infiltration in the tumor core, which is associated with a poor response to immunotherapy.
Article
Multidisciplinary Sciences
Bruno Carvalho, Jose Manuel Lopes, Roberto Silva, Joana Peixoto, Dina Leitao, Paula Soares, Ana Catarina Fernandes, Paulo Linhares, Rui Vaz, Jorge Lima
Summary: The study found that overexpression of c-Met and VEGFR2 in GBM patients is associated with poor prognosis following treatment with bevacizumab. Co-overexpression of c-Met and VEGFR2 is correlated with worse overall survival.
SCIENTIFIC REPORTS
(2021)
Article
Cardiac & Cardiovascular Systems
Silvia Fanti, Edward Stephenson, Etel Rocha-Vieira, Alexandros Protonotarios, Stavroula Kanoni, Eriomina Shahaj, M. Paula Longhi, Vishal S. Vyas, Carlene Dyer, Elena Pontarini, Angeliki Asimaki, Carlos Bueno-Beti, Monica De Gaspari, Stefania Rizzo, Cristina Basso, Michele Bombardieri, David Coe, Guosu Wang, Daniel Harding, Iain Gallagher, Egle Solito, Perry Elliott, Stephane Heymans, Maurits Sikking, Konstantinos Savvatis, Saidi A. Mohiddin, Federica M. Marelli-Berg
Summary: This study found that c-Met(+) T cells were selectively increased in the peripheral blood and myocardium of patients with inflammatory cardiomyopathies, and they exhibited distinct phenotype and function compared to c-Met(-) T cells. Different subpopulations of circulating c-Met(+) T cells in different heart muscle diseases were associated with distinct and overlapping mechanisms of heart inflammation. Pharmacologic inhibition of c-Met could halt the development of disease, indicating a causative role for c-Met(+) T cells.
Article
Oncology
Pierluigi Calo, Nicolas Pianton, Alexandre Basle, Alexandre Vasiljevic, Marc Barritault, Pierre Aurelien Beuriat, Cecile Faure-Conter, Pierre Leblond
Summary: Currently, there is no clear consensus on the best treatment for children with optic pathway gliomas (OPG). Different chemotherapy regimens have been proposed, but none have proven superiority in terms of progression-free survival (PFS). Recent publications have suggested that the combination of bevacizumab and irinotecan may be effective, although irinotecan has shown digestive side effects. This retrospective study evaluated the efficacy of bevacizumab used as a single agent in children with OPG, and found promising results in terms of tumor response rate and disease control.
Article
Oncology
Soufyan Annakib, Valerie Rigau, Amelie Darlix, Catherine Goze, Hugues Duffau, Luc Bauchet, Marta Jarlier, Michel Fabbro
Summary: This study retrospectively evaluated the clinical outcomes of bevacizumab as rescue treatment for recurrent WHO grades II-III glioma, and found that bevacizumab displayed prolonged activity in a subset of patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Cell Biology
Pijus K. Barman, Juliana E. Shin, Sloan A. Lewis, Seokjo Kang, Di Wu, Yizhou Wang, Xiaoming Yang, Prakash S. Nagarkatti, Mitzi Nagarkatti, Ilhem Messaoudi, Berenice A. Benayoun, Helen S. Goodridge
Summary: Aging is associated with increased monocyte production as well as altered function, with classical monocytes in old mice showing higher expression of DCMo signature genes. This leads to increased production of moDC in old mice. Additionally, higher expression of Aw112010 in old monocytes may be linked to elevated MHCII expression, indicating a potential mechanism for altered monocyte function during aging.
Article
Immunology
Silvia Oggero, Chiara Cecconello, Rita Silva, Lynda Zeboudj, George Sideris-Lampretsas, Mauro Perretti, Marzia Malcangio
Summary: This study found that CX3CR1-expressing monocytes and macrophages infiltrate the lumbar dorsal root ganglia (DRG) in rheumatoid arthritis (RA), and neurons up-regulate neuropeptide CGRP. Inhibiting CX3CR1 and CGRP can alleviate arthritis pain.
BRAIN BEHAVIOR AND IMMUNITY
(2022)
Article
Medicine, Research & Experimental
Adele Mucci, Gabriele Antonarelli, Carolina Caserta, Francesco Maria Vittoria, Giacomo Desantis, Riccardo Pagani, Beatrice Greco, Monica Casucci, Giulia Escobar, Laura Passerini, Nico Lachmann, Francesca Sanvito, Matteo Barcella, Ivan Merelli, Luigi Naldini, Bernhard Gentner
Summary: Understanding the immunosuppressive microenvironment around tumor cells and reprogramming the immune system through gene transfer have shown promising results in inhibiting tumor progression and enhancing T cell recruitment and activation. The activity of interferon-gamma can be further enhanced by co-delivery of other immune factors or drugs blocking immunosuppressive escape pathways, showing potential for obtaining durable responses.
EMBO MOLECULAR MEDICINE
(2021)
Article
Neurosciences
Ruoyu Huang, Yanwei Liu, Kuanyu Wang, Zheng Wang, Chuanbao Zhang, Wei Zhang, Zheng Zhao, Guanzhang Li, Lijie Huang, Yuanhao Chang, Fan Zeng, Tao Jiang, Huimin Hu
Summary: PTPRZ1-MET (ZM) fusion is a critical driver of lower-grade glioma progression and a potential target for MET inhibitors. Early detection using a high-sensitive method of reverse transcriptase PCR is crucial for identifying patients who may benefit from MET inhibitor therapy. The hyperactivation of MET signaling in glioma with ZM fusion may be due to ligand-independent activation enabled by the protein structure modification of the extracellular domain of MET.
CNS NEUROSCIENCE & THERAPEUTICS
(2021)
Article
Biochemistry & Molecular Biology
Natalia Lehman, Wioleta Kowalska, Michal Zarobkiewicz, Marek Mazurek, Karolina Mrozowska, Agnieszka Bojarska-Junak, Radoslaw Rola
Summary: Monocyte subpopulations in glioma patients' peripheral blood were analyzed based on CD14, CD16, and SLAN expression. The study found different profiles of monocytes with varying cytokine expression. The presence of these different profiles might hinder the effectiveness of immunotherapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Katherine Green, Paraskevi Panagopoulou, Felice D'Arco, Patricia O'Hare, Richard Bowman, Bronwen Walters, Christine Dahl, Mette Jorgensen, Pritesh Patel, Olga Slater, Rehana Ahmed, Simon Bailey, Fernando Carceller, Rhiannon Collins, Elizabeth Corley, Martin English, Lisa Howells, Ahmed Kamal, John-Paul J. P. Kilday, Stephen Lowis, Blanche Lumb, Erika Pace, Susan Picton, Barry Pizer, Ayad Shafiq, Lena Uzunova, Harriet Wayman, Shaun Wilson, Darren Hargrave, Enrico Opocher
Summary: A nationwide UK service evaluation on the use of bevacizumab in children with pediatric low-grade glioma (PLGG) showed that it can effectively control short-term progression of PLGG and significantly improve visual outcomes. However, there are potential toxicities and risks of further progression, highlighting the need for further research to optimize the treatment strategy of bevacizumab.
Article
Medicine, Research & Experimental
Katrin Radloff, Birgitt Gutbier, Charlotte Maeve Dunne, Hanieh Moradian, Marko Schwestka, Manfred Gossen, Katharina Ahrens, Laura Kneller, Yadong Wang, Akanksha Moga, Leonidas Gkionis, Oliver Keil, Volker Fehring, Daniel Tondera, Klaus Giese, Ansgar Santel, Joerg Kaufmann, Martin Witzenrath
Summary: Dysfunction of endothelial cells leads to various diseases, and therapeutic modulation of gene expression is important for treating diseases like lung edema. This study tested a new synthetic mRNA formulation to attenuate inflammation-induced vascular leakage, showing promising results.
MOLECULAR THERAPY NUCLEIC ACIDS
(2023)